Manas AI develops medicines by integrating foundational AI technologies with deep domain expertise in biology and chemistry across the entire clinical pipeline. The company builds neuro-symbolic models that codify scientific rules to accelerate target identification, candidate generation, and optimization for various therapeutic modalities. This AI-augmented approach aims to deliver faster, more precise drug candidates through efficient preclinical testing and global clinical trials.
Funding
$24.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RHFounders
Product
Problem
Traditional drug discovery processes are lengthy and costly, often taking over a decade and significant capital to bring a new therapeutic to market. This extended timeline delays patient access to potentially life-saving treatments for critical diseases like cancer and rare conditions.
Solution
Manas AI accelerates therapeutic discovery by integrating proprietary AI and generative computational chemistry with advanced biological insights. The platform is designed to identify high-potential therapeutic candidates with enhanced speed and accuracy, thereby reducing the overall timeline and cost associated with traditional drug development. By leveraging AI-driven approaches, Manas AI aims to expedite the identification and advancement of novel chemical entities. The company's full-stack development model supports projects from initial target identification through to clinical trials, with an initial focus on oncology and rare diseases.
Target Audience
Manas AI targets pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and development, particularly those focused on oncology and rare diseases.
Features
- Proprietary AI filters and generative computational chemistry for bespoke chemical library generation.
- Advanced AI models for identifying high-potential therapeutic candidates with increased speed and accuracy.
- Partnership with Microsoft Azure for large-scale compute capabilities, enabling molecular docking speeds significantly faster than conventional systems.
- Project Cosmos initiative focused on mapping fundamental drug binding "rules" to facilitate reverse engineering of novel chemical entities.
- Full-stack development capabilities, supporting projects from target identification to clinical trials.
- Initial therapeutic focus on oncology, including aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma.
- Scientific Advisory Board composed of leading experts in AI, computational chemistry, biology, and clinical research.